FANJ
ICPT

Financial Architects (New Jersey)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Financial Architects (New Jersey)’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed -$22K – 1524
2019
Q1 		$22K Buy
+200
New +$21.9K ﹤0.01% 866
2018
Q2 		– Sell
-100
Closed -$6K – 1554
2018
Q1 		$6K Buy
+100
New +$6.03K ﹤0.01% 1210

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Financial Architects (New Jersey)'s ICPT Position: Q1 2018 in Review

Financial Architects (New Jersey) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2018, closing a stake of 300 shares — an estimated $18.1K sold.

Financial Architects (New Jersey) first reported a position in ICPT in Q2 2016 and held it in 7 quarters. The position peaked at $49K in Q3 2016. 147 funds tracked by Wall St. Rank hold ICPT as of Q1 2018.

  • Financial Architects (New Jersey) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 300 Intercept Pharmaceuticals, Inc. shares in Q1 2018, an estimated $18.1K.
  • Financial Architects (New Jersey) first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
  • Financial Architects (New Jersey)'s Intercept Pharmaceuticals, Inc. position peaked at $49K in Q3 2016.
  • 147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2018, filed 23 Apr 2018.